Non-Vitamin K Antagonist Oral Anticoagulant Treatment in Centenarians: A Series of Four Cases
- 32 Downloads
The increasing life expectancy has resulted in an ever-increasing proportion of the elderly in the general population , and it is estimated that the overall proportion of individuals aged 60 years and above will reach 2 billion by 2050. It is to be expected that the prevalence of age-associated disease, such as atrial fibrillation, will rise in parallel . While there is overwhelming evidence that anticoagulation is critical for stroke prevention in patients diagnosed with atrial fibrillation, anticoagulation is reportedly underprescribed in elderly patients . One of the reasons for withholding anticoagulants is a tendency to overestimate the incidence of intracranial hemorrhage. It has been established that the effectiveness of treatment with non-vitamin K antagonist oral anticoagulant (NOAC) agents is not inferior to that of vitamin K antagonists (VKAs) in populations with an average age of 70–73 years . A 2018 observational study on elderly ethnic Chinese (aged 85 years...
Compliance with Ethical Standards
This study was approved by the local Ethics Committee, Sheba Medical Center, Israel (authorization number 4205-17-SMC).
Conflict of interest
Yuval Kuntzman, Eyal Zimlichman, Howard Amital and Shmuel Tiosano declare no conflicts of interest.
No funding was received for this study.